I heard from two urologists that Decipher was developed to decide on active surveillance in low and intermediate-low risk cases. They don’t think it has much value in higher risk categories.

That said, it is being used to determine duration of ADT with RT and research has shown ir to be a predictor of recurrence risk in high risk Pc.

Knowing your Decipher win’t change your treatment decision, but it is still information you would like to have.